The impact of PC exposure on the incidence of TEARDS was determined by a Bayesian regression model to compare treatment groups. The model adjusted for baseline covariates using a normal distribution with large variance as a noninformative prior on the regression coefficients. Results were adjusted by baseline primary disease therapy strata, cardiac disease history, pulmonary disease history, and transfusion reaction history. Treatment group as well as any additional covariates were included as fixed-level effects. Risk ratios and their associated credible intervals, along with the posterior probability of superiority for the treatment group, are shown. For all mITT patients, the probability of PRPC superiority of a lower incidence of TEARDS is 88.8 % in this model. For patients exposed to ≥2 PCs, the probability of PRPC superiority of a lower incidence of TEARDS is 87.3 % in this model. The probability that PRPC were superior to CPC for lower incidence of TEARDS is 90.1 % for patients exposed to 5 to 10 PCs and 98.8% for patients exposed to >10 PCs. For patients with limited exposures (1 PC and 2-4 PC), the incidence of TEARDS was not informative.